Non-alcoholic fatty liver disease is not associated with impairment in health-related quality of life in virally suppressed persons with human immune deficiency virus.

Autor: Gawrieh S; Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, United Sates of America., Corey KE; Liver Center, Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America., Lake JE; Division of Infectious Diseases, Department of Medicine, University of Texas Health Science Center at Houston, Houston, Texas, United States of America., Samala N; Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, United Sates of America., Desai AP; Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, United Sates of America., Debroy P; Division of Infectious Diseases, Department of Medicine, University of Texas Health Science Center at Houston, Houston, Texas, United States of America., Sjoquist JA; Liver Center, Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America., Robison M; Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, United Sates of America., Tann M; Department of Radiology, Indiana University School of Medicine, Indianapolis, Indiana, United States of America., Akisik F; Department of Radiology, Indiana University School of Medicine, Indianapolis, Indiana, United States of America., Bhamidipalli SS; Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, Indiana, United States of America., Saha CK; Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, Indiana, United States of America., Zachary K; Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America., Robbins GK; Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America., Gupta SK; Division of Infectious Diseases, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, United States of America., Chung RT; Liver Center, Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America., Chalasani N; Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, United Sates of America.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2023 Feb 10; Vol. 18 (2), pp. e0279685. Date of Electronic Publication: 2023 Feb 10 (Print Publication: 2023).
DOI: 10.1371/journal.pone.0279685
Abstrakt: Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in persons with HIV (PWH) (HIV-NAFLD). It is unknown if HIV-NAFLD is associated with impairment in health-related quality of life (HRQOL). We examined HRQOL in PWH with and without NAFLD, compared HRQOL in HIV- versus primary NAFLD, and determined factors associated with HRQOL in these groups. Prospectively enrolled 200 PWH and 474 participants with primary NAFLD completed the Rand SF-36 assessment which measures 8 domains of HRQOL. Individual domain scores were used to create composite physical and mental component summary scores. Univariate and multivariate analyses determined variables associated with HRQOL in PWH and in HIV- and primary NAFLD. In PWH, 48% had HIV-NAFLD, 10.2% had clinically significant fibrosis, 99.5% were on antiretroviral therapy, and 96.5% had HIV RNA <200 copies/ml. There was no difference in HRQOL in PWH with or without NAFLD. Diabetes, non-Hispanic ethnicity, and nadir CD4 counts were independently associated with impaired HRQOL in PWH. In HIV-NAFLD, HRQOL did not differ between participants with or without clinically significant fibrosis. Participants with HIV-NAFLD compared to those with primary NAFLD were less frequently cisgender females, White, more frequently Hispanic, had lower BMI and lower frequency of obesity and diabetes. HRQOL of individuals with HIV-NAFLD was not significantly different from those with primary NAFLD. In conclusion, in virally suppressed PWH, HRQOL is not different between participants with or without HIV-NAFLD. HRQOL is not different between HIV-NAFLD and primary NAFLD.
Competing Interests: Dr. Gawrieh consulting: TransMedics, Pfizer. Research grant support: Cirius, Galmed, Viking and Zydus. Dr. Corey serves on the scientific advisory board for Theratechnologies, Novo Nordisk and BMS and has received grant funding from Boehringer-Ingelheim, BMS and Novartis, Dr. Lake receives research support from Gilead Sciences and Zydus. In the past 12 months she has received research support from Pfizer, CytoDyn, and Oncoimmune, and has served as a consultant to Merck and Theratechnologies, Dr. Samala, Dr. Desai, Dr. Debroy, Ms.Sjoquist, Ms. Robison, Ms. Bhamidipalli, Dr. Saha, Dr. Zachary, Dr. Akisik, and Dr. Tann have nothing to disclose. Dr. Robbin has served as a consultant for SEED , Dr. Gupta reports consultancy/advisory fees from Gilead Sciences, Inc. and ViiV Healthcare and research support from the NIH, Indiana University School of Medicine, and ViiV HealthCare, Dr. Chung has received research grant support (to institution) from Boehringer Ingelheim, BMS, Roche, Gilead, Janssen, and GSK , Dr. Chalasani has ongoing research support from Eli Lilly, Galectin Therapeutics, Intercept, and Exact Sciences, In the past 12 months, he has received consulting fees from Abbvie, Madrigal, Nusirt, Allergan, Siemens, Genentech, Zydus, La Jolla, Axcella, Foresite Labs, and Galectin Therapeutics. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
(Copyright: © 2023 Gawrieh et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje